May 2nd 2024
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Prostate cancer guideline update includes genomically informed therapies
June 20th 2019Integration of tumor genetic testing and genomically-informed therapies into clinical practice for patients with advanced prostate cancer are featured in updated National Comprehensive Cancer Network guidelines on the management of prostate cancer (version 2.2019).
Lifestyle intervention may mitigate metabolic sequelae of ADT
June 12th 2019Following a program that combines a low carbohydrate diet and modest walking may be an effective strategy for blocking many of the adverse metabolic effects of androgen deprivation therapy, according to findings of a randomized controlled trial.
African-Americans fare better with mCRPC treatments vs. Caucasians
May 7th 2019African-American men with metastatic castration-resistant prostate cancer who were treated with abiraterone acetate (ZYTIGA) or enzalutamide (XTANDI) and who had not received prior chemotherapy lived 20% longer over 5 years compared with their Caucasian counterparts.
Germline mutations linked to grade reclassification during AS
April 11th 2019Men with prostate cancer who are carriers of germline pathogenic mutations in the DNA repair genes BRCA1/2 and ATM are at increased risk for grade reclassification during active surveillance, according to research reported by H. Ballentine Carter, MD, at the 2018 AUA annual meeting in San Francisco.
Intermediate-risk PCa: Urinary complications lowest with brachytherapy
April 8th 2019Among the treatment options for intermediate-risk prostate cancer, brachytherapy is associated with the lowest 10-year rate of severe urinary complications while radical prostatectomy most often resulted in the use of devices to treat erectile dysfunction, according to findings from a retrospective analysis of patients who underwent treatment between 2004 and 2007.
Residency vs. the real world: 5 things I wish I’d known
April 2nd 2019"Just like I’ve learned that the grass really isn’t any greener on the other side, I am learning that life in the trenches of urology, as a small-town urologist, isn't exactly what I thought it would be when I was a resident," writes Dr. Rosevear.
Patients on AS still undergo unnecessary biopsies
February 14th 2019Active surveillance is only moderately able to reduce the harmful effects of prostate cancer overdiagnosis from PSA testing, according to an analysis of the long-term outcomes of men enrolled in the Prostate Cancer Research International Active Surveillance program.
Findings question validity of large PCa trial
February 14th 2019According to the updated report from the Prostate Cancer Intervention versus Observation Trial (PIVOT), radical prostatectomy had no significant benefit over observation for reducing mortality among men with clinically localized disease.
High paternal age may raise PCa rate
December 12th 2018The public health impact of increasing paternal age requires further investigation, and clinicians should discuss with their patients the potential impact older fathers may have on their children, according to researchers at Stanford University School of Medicine, Stanford, CA.